Eva Caroff

USPTO Granted Patents = 14 (Patent Applications = 2)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 63(Granted Patents)

Location History:

Ranspach-le-Haut, FR (2010 - 2013)
Allschwil, CH (2012 - 2019)

Company Filing History:

10 out of 217

Actelion Pharmaceuticals Ltd

patents

4 out of 77

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2010-2019

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10259807 - 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives (2019-04-16),

2. 10053457 - Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators (2018-08-21),

3. 10047080 - (R)-2-methyl-piperazine derivatives as CXCR3 receptor modulators (2018-08-14),

4. 9951063 - 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives (2018-04-24),

5. 9266876 - 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives (2016-02-23),

6. 8664203 - Thiazole derivatives and their use as P2Y12 receptor antagonists (2014-03-04),

7. 8518912 - [object Object] (2013-08-27),

8. 8466156 - 2-phenyl-4-cyclopropyl-pyrimidine derivatives (2013-06-18),

9. 8288385 - 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines (2012-10-16),

10. 8093250 - 2-aminocarbonyl-pyridine derivatives (2012-01-10),

11. 8058263 - Substituted 2-phenyl-pyridine derivatives (2011-11-15),

12. 8048881 - Pyrimidine derivatives and their use as P2Y12 receptor antagonists (2011-11-01),

13. 8044055 - 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor (2011-10-25),

14. 7727979 - Guanidine derivatives and their use as neuropeptide FF receptor antagonists (2010-06-01),

Title: Innovator Spotlight: Eva Caroff

Introduction

Eva Caroff is an accomplished inventor based in Allschwil, Switzerland. With an impressive portfolio of 14 patents, she has made significant contributions to the field of pharmaceuticals, particularly in developing new compounds that target the CXCR3 receptor. Her work has the potential to enhance medical treatments and improve patient outcomes.

Latest Patents

Caroff's recent patents showcase her innovative approach to drug development. One of her notable inventions involves 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives. This invention relates to compounds that are used as modulators of the CXCR3 receptor, along with their pharmaceutically acceptable salts. Another significant patent from her portfolio includes hydroxyalkyl-piperazine derivatives, which are also designed as modulators of the CXCR3 receptor, highlighting her focus on impactful medicinal chemistry.

Career Highlights

Throughout her career, Eva Caroff has worked with leading pharmaceutical companies such as Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd. Her experience in these reputable organizations has allowed her to refine her skills and contribute significantly to drug development efforts aimed at addressing complex health issues.

Collaborations

In her journey as an inventor, Caroff has collaborated with esteemed professionals such as Emmanuel Meyer and Kurt Hilpert. These partnerships reflect her ability to work within teams, fostering innovation through shared expertise and collective problem-solving.

Conclusion

Eva Caroff's work exemplifies the spirit of innovation in pharmaceuticals. With her 14 patents, she continues to pave the way for advancements in medicinal compounds, particularly those that influence the CXCR3 receptor. Her contributions are of great relevance to the ongoing quest for effective medical treatments, making her a notable figure in the field of invention.

This text is generated by artificial intelligence and may not be accurate.